The invention relates to a combination which comprises (a) a DNA damaging agent； and (b) 4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidioyl]amino]-N-[5-(4-methyl-1H-imidazol-1-yl)-3-(trifluoromethyl)phenyl]benzamide (“nilotinib”)； a pharmaceutical composition comprising such a combination and optionally at least one pharmaceutical acceptable carrier for simultaneous, separate or sequential use, in particular for the treatment chronic lymphocytic leukemia (CLL)； the use of such a combination for the preparation of a medicament for the treatment of CLL； a commercial package or product comprising such a combination； and to a method of treatment of a warm-blooded animal, especially a human.
